Clinical Trial Update: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update of alisertib (MLN8237) in relapsed or refractory aggressive B-cell lymphomas treated with rituximab with or without vincristine; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• MLN8237 (alisertib) (alisertib)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-03-27